Shamburg News · 8-K filed Nov 12, 2026, 4:20 PM EST

Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Update

SCTX · Scribe Therapeutics, Inc.

  • Earnings
  • Materiality: high

Scribe Therapeutics Inc. reported financial results for the quarter ended September 30, 2026, with collaboration revenue of $1.6 million and a net loss of $9.9 million, or $0.68 per basic and diluted share. Cash, cash equivalents, and marketable securities were $174.2 million as of September 30, 2026, which the company expects to fund operations into the first half of 2029. The results were furnished in Exhibit 99.1 under Item 2.02.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-458486.

Written from the filing by Shamburg Markets. Figures are as reported by the company.